Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus
- First Posted Date
- 2018-04-19
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT03502694
- Locations
- ๐ซ๐ท
Hรดpital Tenon, Paris, France
๐บ๐ธMemorialCare Research Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States
๐บ๐ธLake Internal Medicine Associates, Eustis, Florida, United States
A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older
- Conditions
- Healthy
- Interventions
- Biological: PlaceboBiological: ExPEC4V
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT03500679
- Locations
- ๐บ๐ธ
Heartland Clinical Research, Wichita, Kansas, United States
๐บ๐ธVGR & NOCCR - Knoxville, Knoxville, Tennessee, United States
A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2021-03-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 38
- Registration Number
- NCT03496974
- Locations
- ๐บ๐ธ
Florida Academic Centers Research & Education, Coral Gables, Florida, United States
A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants
- Conditions
- Healthy
- Interventions
- Other: Placebo Matched to MoxifloxacinOther: Placebo Matched to Seltorexant
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 52
- Registration Number
- NCT03494907
- Locations
- ๐ง๐ช
Clinical Pharmacology Unit, Merksem, Belgium
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Conditions
- Diabetes Mellitus, Type 2Cardiovascular Diseases
- Interventions
- Drug: Dipeptidyl Peptidase-4 (DPP-4) InhibitorsDrug: Glucagon-like Peptide-1 (GLP-1) AgonistDrug: Anti-hyperglycemic Agents (AHA)Drug: Thiazolidinediones (TZD)Drug: Sulfonylureas (SU)
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 714582
- Registration Number
- NCT03492580
- Locations
- ๐บ๐ธ
Janssen Investigative Site, Titusville, New Jersey, United States
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants
- Conditions
- Obesity
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 474
- Registration Number
- NCT03486392
- Locations
- ๐ง๐ช
CSL Arlon, Arlon, Belgium
๐ง๐ชAZ Delta, Roeselare, Belgium
๐จ๐ฆClinique des Maladies Lipidiques de Quรฉbec, Quรฉbec, Quebec, Canada
A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events
- Conditions
- Achilles TendonRetinal DetachmentAneurysm, Dissecting
- Interventions
- Drug: Oral Fluoroquinolones (FQ)Drug: Other AntibioticsOther: Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 117911
- Registration Number
- NCT03479736
- Locations
- ๐บ๐ธ
Janssen Investigative Site, Titusville, New Jersey, United States
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 125
- Registration Number
- NCT03473743
- Locations
- ๐ง๐พ
Grodno University Hospital, Grodno, Belarus
๐ง๐พState Institution N.N. Alexandrov Republican Scientific and, Lesnoy, Belarus
๐ง๐พMinsk city Clinical Oncological Dispensary, Minsk, Belarus
A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Participants
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT03468777
- Locations
- ๐ง๐ช
Clinical Pharmacology Unit, Merksem, Belgium
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
- Conditions
- Crohn's Disease
- Interventions
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1409
- Registration Number
- NCT03466411
- Locations
- ๐ง๐พ
Grodno University Hospital, Grodno, Belarus
๐ง๐พHealthcare Institution,Minsk Scientific center for surgery,, Minsk, Belarus
๐ง๐พVitebsk Regional Clinical Hospital, Vitebsk, Belarus